

Annukka Pasanen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2432647/publications.pdf>

Version: 2024-02-01

38
papers

763
citations

687363

13
h-index

552781

26
g-index

39
all docs

39
docs citations

39
times ranked

1123
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 1315-1320.	7.1	166
2	Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability. <i>ELife</i> , 2018, 7, .	6.0	58
3	Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. <i>Nature</i> , 2021, 596, 398-403.	27.8	53
4	PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells. <i>American Journal of Surgical Pathology</i> , 2020, 44, 174-181.	3.7	52
5	Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma. <i>Modern Pathology</i> , 2020, 33, 1443-1452.	5.5	51
6	Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas. <i>Scientific Reports</i> , 2017, 7, 1015.	3.3	44
7	L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1465-1471.	2.5	30
8	Global metabolomic profiling of uterine leiomyomas. <i>British Journal of Cancer</i> , 2017, 117, 1855-1864.	6.4	29
9	Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas. <i>Gynecologic Oncology</i> , 2018, 150, 92-98.	1.4	29
10	Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 471-479.	2.8	27
11	Molecular changes preceding endometrial and ovarian cancer: a study of consecutive endometrial specimens from Lynch syndrome surveillance. <i>Modern Pathology</i> , 2018, 31, 1291-1301.	5.5	25
12	Risk-stratification of endometrial carcinomas revisited: A combined preoperative and intraoperative scoring system for a reliable prediction of an advanced disease. <i>Gynecologic Oncology</i> , 2015, 137, 23-27.	1.4	24
13	Mismatch repair protein and <i>MLH1</i> methylation status as predictors of response to adjuvant therapy in endometrial cancer. <i>Cancer Medicine</i> , 2021, 10, 1034-1042.	2.8	23
14	Altered glycosylation of glycodelin in endometrial carcinoma. <i>Laboratory Investigation</i> , 2020, 100, 1014-1025.	3.7	16
15	Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort. <i>Gynecologic Oncology</i> , 2017, 144, 510-514.	1.4	13
16	L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma. <i>Gynecologic Oncology</i> , 2017, 146, 615-622.	1.4	12
17	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. <i>PLoS ONE</i> , 2020, 15, e0242733.	2.5	12
18	Preoperative Risk Stratification of Endometrial Carcinoma: L1CAM as a Biomarker. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1318-1324.	2.5	11

#	ARTICLE	IF	CITATIONS
19	3â€²RNA Sequencing Accurately Classifies Formalin-Fixed Paraffin-Embedded Uterine Leiomyomas. <i>Cancers</i> , 2020, 12, 3839.	3.7	9
20	Clinicopathologic vs. Molecular Integrated Prognostication of Endometrial Carcinoma by European Guidelines. <i>Cancers</i> , 2022, 14, 651.	3.7	9
21	Mismatch Repair Deficiency as a Predictive and Prognostic Biomarker in Molecularly Classified Endometrial Carcinoma. <i>Cancers</i> , 2021, 13, 3124.	3.7	8
22	TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma. <i>Gynecologic Oncology</i> , 2022, 165, 577-584.	1.4	8
23	Histopathologic and Molecular Characterization of Uterine Leiomyomaâ€™like Inflammatory Myofibroblastic Tumor. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1126-1136.	3.7	8
24	Molecular classification of endometrial carcinoma: a clinically oriented review. <i>Journal of Clinical Pathology</i> , 0, , jclinpath-2022-208345.	2.0	8
25	Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma. <i>PLoS ONE</i> , 2021, 16, e0253472.	2.5	7
26	Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma - Emphasis on tumor grade. <i>Gynecologic Oncology</i> , 2022, 164, 187-194.	1.4	6
27	Incidence of and risk factors for surgical site infections in women undergoing hysterectomy for endometrial carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 480-485.	2.8	5
28	<i>MED12</i> mutations and fumarate hydratase inactivation in uterine adenomyomas. <i>Human Reproduction Open</i> , 2018, 2018, hoy020.	5.4	5
29	American Society of Anesthesiologists physical status score as a predictor of long-term outcome in women with endometrial cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 879-885.	2.5	5
30	Low Expression of Stanniocalcin 1 (STC-1) Protein Is Associated With Poor Clinicopathologic Features of Endometrial Cancer. <i>Pathology and Oncology Research</i> , 2021, 27, 1609936.	1.9	4
31	Testing for Lynch Syndrome in Endometrial Carcinoma: From Universal to Age-Selective MLH1 Methylation Analysis. <i>Cancers</i> , 2022, 14, 1348.	3.7	3
32	Parity associates with chromosomal damage in uterine leiomyomas. <i>Nature Communications</i> , 2021, 12, 5448.	12.8	2
33	Abstract 436: Glycodelin expression in endometrial carcinoma. <i>Cancer Research</i> , 2016, 76, 436-436.	0.9	1
34	Abstract 120: Estrogen and progesterone receptor expression in different molecular uterine leiomyoma subclasses. , 2016, , .		0
35	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0
36	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0

#	ARTICLE	IF	CITATIONS
37	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0
38	Clinical factors as prognostic variables among molecular subgroups of endometrial cancer. , 2020, 15, e0242733.		0